162 related articles for article (PubMed ID: 37994866)
21. Nectin-4 is frequently expressed in primary salivary gland cancer and corresponding lymph node metastases and represents an important treatment-related biomarker.
Mayer M; Nachtsheim L; Prinz J; Shabli S; Suchan M; Klußmann JP; Quaas A; Arolt C; Wolber P
Clin Exp Metastasis; 2023 Oct; 40(5):395-405. PubMed ID: 37480387
[TBL] [Abstract][Full Text] [Related]
22. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
Mantia CM; Sonpavde G
Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
[TBL] [Abstract][Full Text] [Related]
23. Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review.
Bantounou MA; Plascevic J; MacDonald L; Wong MC; O'Connell N; Galley HF
Curr Urol; 2023 Dec; 17(4):271-279. PubMed ID: 37994340
[TBL] [Abstract][Full Text] [Related]
24. Nectin-4: a Tumor Cell Target and Status of Inhibitor Development.
Bouleftour W; Sargos P; Magne N
Curr Oncol Rep; 2023 Mar; 25(3):181-188. PubMed ID: 36696077
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
[TBL] [Abstract][Full Text] [Related]
26. Nectin-4: a Novel Therapeutic Target for Skin Cancers.
Hashimoto H; Tanaka Y; Murata M; Ito T
Curr Treat Options Oncol; 2022 Apr; 23(4):578-593. PubMed ID: 35312963
[TBL] [Abstract][Full Text] [Related]
27. Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
Bahlinger V; Branz A; Strissel PL; Strick R; Lange F; Geppert CI; Klümper N; Hölzel M; Wach S; Taubert H; Sikic D; Wullich B; Angeloni M; Ferrazzi F; Diehl L; Kovalenko M; Elboudwarej E; Jürgensmeier JM; Hartmann A; Eckstein M
Histopathology; 2024 Apr; 84(5):863-876. PubMed ID: 38196202
[TBL] [Abstract][Full Text] [Related]
28. New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?
Audisio M; Tucci M; Di Stefano RF; Parlagreco E; Ungaro A; Turco F; Audisio A; Di Prima L; Ortega C; Di Maio M; Scagliotti GV; Buttigliero C
Crit Rev Oncol Hematol; 2022 Jun; 174():103682. PubMed ID: 35421529
[TBL] [Abstract][Full Text] [Related]
29. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
30. Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
Zhou W; Fang P; Yu D; Ren H; You M; Yin L; Mei F; Zhu H; Wang Z; Xu H; Cao Y; Sun X; Xu X; Bi J; Wang J; Ma L; Wang X; Chen L; Zhang Y; Cen X; Zhu X; Lou L; Liu D; Tan X; Yang J; Meng T; Shen J
Mol Cancer Ther; 2023 Aug; 22(8):913-925. PubMed ID: 37196158
[TBL] [Abstract][Full Text] [Related]
31. Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin.
Hanna KS
J Adv Pract Oncol; 2020; 11(4):412-417. PubMed ID: 33604101
[TBL] [Abstract][Full Text] [Related]
32. Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin.
Cho WC; Saade R; Nagarajan P; Aung PP; Milton DR; Marques-Piubelli ML; Hudgens C; Ledesma D; Nelson K; Ivan D; Zhang M; Torres-Cabala CA; Campbell M; Alhalabi O; Prieto VG; Wistuba II; Esmaeli B; Curry JL
J Cutan Pathol; 2024 May; 51(5):360-367. PubMed ID: 38200650
[TBL] [Abstract][Full Text] [Related]
33. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors.
Rigby M; Bennett G; Chen L; Mudd GE; Harrison H; Beswick PJ; Van Rietschoten K; Watcham SM; Scott HS; Brown AN; Park PU; Campbell C; Haines E; Lahdenranta J; Skynner MJ; Jeffrey P; Keen N; Lee K
Mol Cancer Ther; 2022 Dec; 21(12):1747-1756. PubMed ID: 36112771
[TBL] [Abstract][Full Text] [Related]
34. Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
Maiorano BA; Catalano M; Maiello E; Roviello G
Front Oncol; 2023; 13():1254906. PubMed ID: 37781180
[TBL] [Abstract][Full Text] [Related]
35. The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review.
Bouleftour W; Guillot A; Magne N
Mol Cancer Ther; 2022 Apr; 21(4):493-501. PubMed ID: 35131876
[TBL] [Abstract][Full Text] [Related]
36. Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.
Shafique MA; Haseeb A; Siddiq MA; Mussarat A; Rangwala HS; Mustafa MS
Cancer Manag Res; 2023; 15():699-706. PubMed ID: 37485038
[TBL] [Abstract][Full Text] [Related]
37. Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma.
Pace A; Brower B; Conway D; Leis D
Clin J Oncol Nurs; 2021 Apr; 25(2):E1-E9. PubMed ID: 33739346
[TBL] [Abstract][Full Text] [Related]
38. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J; Trepka K; Sjöström M; Egusa EA; Chu CE; Zhu J; Chan E; Gibb EA; Badura ML; Contreras-Sanz A; Stohr BA; Meng MV; Pruthi RS; Lotan Y; Black PC; Porten SP; Koshkin VS; Friedlander TW; Feng FY
Eur Urol Oncol; 2022 Dec; 5(6):714-718. PubMed ID: 35216942
[TBL] [Abstract][Full Text] [Related]
39. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
[TBL] [Abstract][Full Text] [Related]
40. Enfortumab vedotin - next game-changer in urothelial cancer.
Maas M; Stühler V; Walz S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Jul; 21(7):801-809. PubMed ID: 33325754
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
